Peregrine Initiates Patient Treatment in Bavituximab Combination Therapy Cancer Trial

Peregrine Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference

Positive Results From Peregrine's Bavituximab Phase Ia HCV Trial Presented At AASLD Meeting

Peregrine Pharmaceuticals to Present at C.E. Unterberg, Towbin Life Sciences Conference

Peregrine Completes Patient Enrollment in Phase Ib Bavituximab Hepatitis C Trial

Peregrine Pharmaceuticals Announces Annual Meeting Webcast

Peregrine Pharmaceuticals to Present at BIO InvestorForum

Peregrine Receives Regulatory Approval for New Cotara(R) Brain Cancer Clinical Trial

Peregrine Announces Issuance of Broad Patent Covering Vascular Targeting Agents in Combination Therapy Regimens

Researchers Report Peregrine's Phospholipid-Targeted Antibodies Fused With Cytokines Reduce Tumor Growth in Animals by Over 90%